Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Roche Products Limited
Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire, AL7 1TW
Telephone: +44 (0)1707 366 000
Fax: +44 (0)1707 338 297
WWW: http://www.rocheuk.com
Medical Information Direct Line: +44 (0)800 328 1629
Medical Information e-mail: medinfo.uk@roche.com
Customer Care direct line: +44 (0)800 731 5711
Medical Information Fax: +44 (0)1707 384555

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 22/12/2011
PIL Pegasys 180mcg solution for injection in a pre-filled syringe

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 22/12/2011 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 04/07/2011 and displayed until 22/12/2011
Reasons for adding or updating:
  • Change to information about pregnancy or lactation
Updated on 27/04/2011 and displayed until 04/07/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change of contra-indications
Updated on 10/11/2009 and displayed until 27/04/2011
Reasons for adding or updating:
  • Change to side-effects
Updated on 26/08/2009 and displayed until 10/11/2009
Reasons for adding or updating:
  • Change to side-effects
Updated on 12/12/2008 and displayed until 26/08/2009
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 04/07/2008 and displayed until 12/12/2008
Reasons for adding or updating:
  • Change to side-effects
Updated on 08/04/2008 and displayed until 04/07/2008
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 07/12/2007 and displayed until 08/04/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 19/07/2007 and displayed until 07/12/2007
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 20/03/2007 and displayed until 19/07/2007
Reasons for adding or updating:
  • Change to date of revision
Updated on 17/01/2007 and displayed until 20/03/2007
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to date of revision
Updated on 05/12/2006 and displayed until 17/01/2007
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
Updated on 09/08/2006 and displayed until 05/12/2006
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to storage instructions
  • Change to date of revision
Updated on 13/06/2006 and displayed until 09/08/2006
Reasons for adding or updating:
  • Change to information about pregnancy or lactation
  • Change to date of revision
Updated on 07/02/2006 and displayed until 13/06/2006
Reasons for adding or updating:
  • Change to Marketing Authorisation Holder
  • Change to date of revision
  • Change to side-effects
  • Change to storage instructions
  • Change to Further Information section
Updated on 16/03/2005 and displayed until 07/02/2006
Reasons for adding or updating:
  • Change to, or new, use for medicine
  • Change to side-effects
  • Change to Further Information section
  • Change to date of revision
Updated on 20/08/2003 and displayed until 16/03/2005
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
  peginterferon alfa-2a